NVCRNovoCure Ltd同业对比
NovoCure Ltd 与SIC 3841 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NVCR本股 | $1.9B#6 | — | 5.6x#9 | 2.9x#7 | 8.3%#11 | 19.4%#6 | -23.5%#10 | -40.3%#9 | -35.0%#9 | 3#9 | — | — |
| HTFL | $4.2B#1 | 16.2x#1 | 15.0x#13 | 23.9x#14 | 39.9%#2 | -21.1%#12 | -36.4%#13 | -41.8%#10 | — | — | — | — |
| ICUI | $3.9B#2 | 131.0x#6 | 1.8x#2 | 1.7x#3 | -6.3%#14 | 100.6%#3 | 1.9%#6 | 0.0%#6 | 0.3%#4 | 6#4 | 18.0%#3 | — |
| ATRC | $2.9B#3 | 267.9x#7 | 5.5x#8 | 5.4x#10 | 14.9%#6 | 74.4%#4 | -1.8%#7 | -2.2%#8 | -2.3%#5 | 7#1 | 62.4%#1 | — |
| INSP | $2.2B#4 | 16.5x#2 | 2.6x#3 | 2.4x#5 | 13.6%#8 | 171.8%#2 | 5.6%#5 | 17.6%#2 | 7.1%#2 | 7#1 | — | — |
| UFPT | $2.1B#5 | 29.9x#4 | 4.6x#7 | 3.6x#8 | 19.5%#5 | 15.8%#8 | 15.3%#3 | 14.8%#3 | 13.4%#1 | 7#1 | — | — |
| LMAT | $1.8B#7 | 28.0x#3 | 4.4x#6 | 7.3x#11 | 13.5%#10 | 31.1%#5 | 27.2%#2 | 13.7%#4 | — | — | — | 1.0%#2 |
| ATEC | $1.6B#8 | — | — | 2.2x#4 | 25.0%#4 | 11.6%#9 | -10.7%#8 | — | -18.5%#6 | 6#4 | -29.1%#5 | — |
| KMTS | $1.5B#9 | — | 6.8x#10 | 15.8x#13 | 59.0%#1 | -15.6%#11 | -141.6%#14 | -59.2%#12 | -59.5%#10 | 4#8 | — | — |
| AORT | $1.2B#10 | — | 2.8x#4 | 2.8x#6 | 13.6%#9 | 173.1%#1 | 7.6%#4 | 2.2%#5 | 3.0%#3 | 5#7 | -36.0%#6 | 0.3%#3 |
| IART | $1.2B#11 | — | 1.2x#1 | 0.7x#1 | 1.5%#13 | -7389.9%#14 | -30.2%#11 | -49.5%#11 | -32.1%#8 | 6#4 | 3.9%#4 | — |
| TNDM | $1.1B#12 | — | 8.7x#11 | 1.1x#2 | 7.9%#12 | -113.2%#13 | -18.5%#9 | -157.0%#13 | -26.3%#7 | 3#9 | 34.8%#2 | — |
| PRCT | $1.1B#13 | — | 3.2x#5 | 3.6x#9 | 37.2%#3 | -4.5%#10 | -33.7%#12 | -0.0%#7 | -63.4%#11 | 2#11 | — | — |
| IRMD | $1.1B#14 | 46.0x#5 | 10.3x#12 | 12.6x#12 | 14.4%#7 | 16.9%#7 | 31.2%#1 | 22.1%#1 | — | — | — | 1.4%#1 |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-15。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议